New combo therapy aims to fight advanced colorectal cancer

NCT ID NCT07467590

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether a special radiotherapy regimen followed by targeted therapy and immunotherapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatments. About 33 participants will receive the treatment and be monitored for tumor response and survival. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
High- and low-dose radiotherapy followed by anti-angiogenic tyrosine kinase inhibitor (TKI) and anti-PD-1 antibody therapy
What this could lead to
If this works, it could offer a new treatment option for people with advanced colorectal cancer that has not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The combination of treatments may cause side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE RESPONSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.